Changes in Immunologic Indicators During Allergen-Specific Immunotherapy for Allergic Rhinitis and Determinants of Variability: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Restricted accessReview articleFirst published online November, 2021
Changes in Immunologic Indicators During Allergen-Specific Immunotherapy for Allergic Rhinitis and Determinants of Variability: A Systematic Review and Meta-analysis of Randomized Controlled Trials
To date, there are no generally recognized biomarkers for allergen immunotherapy (AIT) and even the changes in immunological indicators during AIT are inconsistent in different publications.
Objective
This study was conducted to quantify the immunological changes that occur during AIT and identify the determinants of heterogeneity.
Methods
Randomized controlled trials of AIT published in the past 10 years were searched in Medline, Embase and Cochrane CENTRAL. Data on immunological indicators were extracted, and the characteristics of the included studies were collected. Meta-analysis and meta-regression were conducted for each indicator. The study was registered on the PROSPERO website (CRD42020176127).
Results
We reviewed 1898 studies. Forty-six studies met the inclusion criteria, and 31 studies were included in the quantitative analyses. Subset analyses by time demonstrated that serum allergen-specific IgE (sIgE) of AIT patients increased in the first 12 months, then decreased and became slightly lower than that of control patients. Allergen-specific IgG4 (sIgG4) was elevated in the AIT group during and after treatment. IgE-blocking factor (IgE-BF) was increased and IgE-facilitated allergen binding (IgE-FAB) was reduced in AIT patients. Both of them of the 2 factors were associated with clinical efficacy in the multivariate regression analysis. sIgE/sIgG4 decreased in AIT patients, while there was no change in total IgE.
Conclusion
The levels of serum sIgE and sIgG4 during AIT showed a time-dependent pattern. IgE-BF and IgE-FAB should be further investigated as biomarkers for predicting and monitoring AIT efficacy.
PfaarODemolyPGerth van WijkR, et al.;European Academy of Allergy and Clinical Immunology.
Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;
69(7):854–867.
2.
ShamjiMHKappenJHAkdisM, et al.
Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper. Allergy. 2017;
72(8):1156–1173.
3.
GómezEFernándezTDDoñaI, et al.
Initial immunological changes as predictors for house dust mite immunotherapy response. Clin Exp Allergy. 2015;
45(10):1542–1553.
4.
ShamjiMHLjørringCFrancisJN, et al.
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;
67(2):217–226.
5.
SchmidJMWurtzenPADahlR, et al.
Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. J Allergy Clin Immunol. 2014;
134(3):741–744.e5.
6.
HigginsJPWhiteIRAnzures-CabreraJ.Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat Med. 2008;
27(29):6072–6092.
7.
Martinez-CoceraCSastreJCimarraM, et al.
Immunotherapy with a phleum pratense allergen extract induces an immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol. 2010;
20(1):13–19.
8.
ShaoJCuiYXZhengYF, et al.
Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol Allergy. 2014;
28(2):131–139.
9.
SongWLinXChaiR. [
Efficacy evaluation of standardized dust mite allergen specific immunotherapy to patients of allergic rhinitis. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = J Clin Otorhinolaryngol Head Neck Surg. 2014;
28(5):300–302.
10.
BergmannKCDemolyPWormM, et al.
Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;
133(6):1608–1614.
11.
CoxLSCasaleTBNayakAS, et al.
Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;
130(6):1327–1334.e1.
12.
DidierAMelacMMontagutA, et al.
Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009;
64(1):166–171.
13.
GunawardanaNCZhaoQCarayannopoulosLN, et al.
The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms. J Allergy Clin Immunol. 2018;
141(2):785–788.
14.
PfaarOWolfHKlimekL, et al.
Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Therapeut. 2012;
34(10):2072–2081.
15.
RouxMDevillierPYangWH, et al.
Efficacy and safety of sublingual tablets of house dust mite allergen extracts: results of a dose-ranging study in an environmental exposure chamber. J Allergy Clin Immunol. 2016;
138(2):451–458.e5.
16.
StelmachIKaczmarek-WozniakJMajakP, et al.
Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009;
39(3):401–408.
17.
WahnUTabarAKunaP, et al.; SLIT Study Group.
Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;
123(1):160–166.
18.
ReichKGessnerCKrokerA, et al.
Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Therapeut. 2011;
33(7):828–840.
19.
CourouxPIpsenHStageBS, et al.
A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. Allergy: Eur J Allergy Clin Immunol. 2019;
74(2):361–369.
20.
DurhamSREmmingerWKappA, et al.
Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;
125(1):131–138.e1-7.
21.
LaursenMKAndersenJSSorensenHF, et al.
Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;
141(2):529–538.
22.
MakelaMJGyllforsPValovirtaE, et al.
Immunotherapy with the SQ tree SLIT-tablet in adults and adolescents with allergic rhinoconjunctivitis. Clin Therapeut. 2018;
40(4):574–586.
23.
MasuyamaKOkamotoYOkamiyaK, et al.
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018;
73(12):2352–2363.
24.
NolteHBernsteinDINelsonHS, et al.
Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;
138(6):1631–1638.
25.
BozekAIgnasiakBFilipowskaB, et al.
House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy. 2013;
43(2):242–248.
26.
BozekAKolodziejczykKKrajewska-WojtysA, et al.
Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass. Ann Allergy Asthma Immunol. 2016;
116(2):156–161.
27.
BozekAKolodziejczykKWarkocka-SzoltysekB, et al.
Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Am J Rhinol Allergy. 2014;
28(5):423–427.
28.
ChakerAMShamjiMHDumitruFA, et al.
Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. J Allergy Clin Immunol. 2016;
137(2):452–461.
29.
CortelliniGSpadoliniIPatellaV, et al.
Sublingual immunotherapy for alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Ann Allergy Asthma Immunol. 2010;
105(5):382–386.
30.
GallegoMTIraolaVHimlyM, et al.
Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response. Int Arch Allergy Immunol. 2010;
153(1):61–69.
31.
MosgesRKascheEMRaskopfE, et al.
A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy: Eur J Allergy Clin Immunol. 2018;
73(4):896–904.
32.
PfaarOUrryZRobinsonDS, et al.
A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy: Eur J Allergy Clin Immunol. 2012;
67(2):272–279.
33.
PrietoLPalaciosRAldanaD, et al.
Effect of allergen-specific immunotherapy with purified alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study. Allergy Asthma Clin Immunol. 2010;
6(1):27.
34.
WangDHChenLChengL, et al.
Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013;
123(6):1334–1340.
35.
XianMFengMDongY, et al.
Changes in CD4+CD25+FoxP3+ regulatory T cells and serum cytokines in sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma. Int Arch Allergy Immunol. 2020;
181(1):71–80.
36.
Kim JH, Lee JH, Ye YM, et al.
Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites. Allergy, asthma & immunology research. 2018;
10(6):675–685.
37.
MeyerWNarkusASalapatekAM, et al.
Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic bet v 1 in an environmental exposure chamber. Allergy: Eur J Allergy Clin Immunol. 2013;
68(6):724–731.
38.
Baron-BodoVHoriotSLautretteA, et al.
Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy. Clin Exp Allergy. 2013;
43(12):1362–1373.
39.
SakuraiDYonekuraSIinumaT, et al.
Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success. Rhinology. 2016;
54(3):221–230.
40.
TabarAIPrietoLAlbaP, et al.
Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen alt a 1. J Allergy Clin Immunol. 2019;
144(1):216–223.
41.
KlimekLBachertCLukatKF, et al.
Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy. 2015;
5:28.
42.
UrraJMCarrascoPFeo-BritoF, et al.
Immunotherapy reduces CD40L expression and modifies cytokine production in the CD4 cells of pollen allergy patients. J Investig Allergol Clin Immunol. 2014;
24(2):98–105.
43.
YukselenAKendirliSGYilmazM, et al.
Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. Asian Pac J Allergy Immunol. 2013;
31(3):233–241.
44.
Karakoc-AydinerEEifanAOBarisS, et al.
Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;
25(5):334–342.
45.
LouWWangCWangY, et al.
Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol. 2012;
23(2):141–149.
46.
StarchenkaSHeathMDLineberryA, et al.
Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy. World Allergy Organ J. 2019;
12(11):100087.
47.
SwamyRSReshamwalaNHunterT, et al.
Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;
130(1):215–224.e7.
48.
Van OvertveltLBaron-BodoVHoriotS, et al.
Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy. 2011;
66(12):1530–1537.
49.
Kepil ÖzdemirSSinBAGüloğluD, et al.
Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response? International archives of. Int Arch Allergy Immunol. 2014;
164(3):237–245.
50.
PinartMKellerTReichA, et al.
Sex-related allergic rhinitis prevalence switch from childhood to adulthood: a systematic review and meta-analysis. Int Arch Allergy Immunol. 2017;
172(4):224–235.
51.
LaiXLiJXiaoX, et al.
Specific IgG4 production during house dust mite immunotherapy among age, gender and allergic disease populations. Int Arch Allergy Immunol. 2013;
160(1):37–46.
52.
SoyyigitSGulogluDIkinciogullariA, et al.
Immunologic alterations and efficacy of subcutaneous immunotherapy with dermatophagoides pteronyssinus in monosensitized and polysensitized patients. Ann Allergy Asthma Immunol. 2016;
116(3):244–251.e2.
53.
KimKWKimEAKwonBC, et al.
Comparison of allergic indices in monosensitized and polysensitized patients with childhood asthma. J Korean Med Sci. 2006;
21(6):1012–1016.
54.
MoingeonP.Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;
1(3):228–241.
55.
FrancisJNDurhamSR.Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol. 2004;
4(6):543–548.
56.
JamesLKShamjiMHWalkerSM, et al.
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011;
127(2):509–516. e1-5.
57.
ZhaoDLaiXTianM, et al.
The functional IgE-blocking factor induced by allergen-specific immunotherapy correlates with IgG4 antibodies and a decrease of symptoms in house dust mite-allergic children. Int Arch Allergy Immunol. 2016;
169(2):113–120.
58.
FengMSuQLaiX, et al.
Functional and immunoreactive levels of IgG4 correlate with clinical responses during the maintenance phase of house dust mite immunotherapy. J Immunol. 2018;
200(12):3897–3904.
59.
ShamjiMHLayhadiJAScaddingGW, et al.
Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. J Allergy Clin Immunol. 2015;
135(4):913–921.e9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
